Axa
RGNX icon

Axa’s Regenxbio RGNX Stock Holding History

Axa’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,700
Closed -$327K – 1344
2019
Q1 		$327K Sell
5,700
-28,400
-83% -$1.41M ﹤0.01% 1176
2018
Q4 		$1.43M Buy
34,100
+20,300
+147% +$1.19M 0.01% 890
2018
Q3 		$1.04M Buy
13,800
+10,900
+376% +$785K ﹤0.01% 1027
2018
Q2 		$208K Buy
+2,900
New +$138K ﹤0.01% 1296
2017
Q2 		– Sell
-226,195
Closed -$4.37M – 1291
2017
Q1 		$4.37M Sell
226,195
-6,875
-3% -$133K 0.02% 624
2016
Q4 		$4.32M Sell
233,070
-211,272
-48% -$4.04M 0.02% 611
2016
Q3 		$6.22M Buy
+444,342
New +$4.9M 0.03% 522

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Axa's RGNX Position: Q2 2019 in Review

Axa sold out of Regenxbio (RGNX) in Q2 2019, closing a stake of 5,700 shares — an estimated $327K sold.

Axa first reported a position in RGNX in Q3 2016 and held it in 7 quarters. The position peaked at $6.22M in Q3 2016. 186 funds tracked by Wall St. Rank hold RGNX as of Q2 2019.

  • Axa reported no remaining Regenxbio position as of Q2 2019 after selling out during the quarter.
  • Axa sold 5,700 Regenxbio shares in Q2 2019, an estimated $327K.
  • Axa first reported a position in Regenxbio in Q3 2016 and held it in 7 quarters.
  • Axa's Regenxbio position peaked at $6.22M in Q3 2016.
  • 186 funds tracked by Wall St. Rank held Regenxbio as of Q2 2019.

Based on Axa's 13F filing for Q2 2019, filed 13 Aug 2019.